Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
PTCH1 is a transmembrane receptor protein and a key component of the Hedgehog (Hh) signaling pathway. It acts as the primary receptor for three ligands: Sonic Hedgehog (SHH), Indian Hedgehog (IHH), and Desert Hedgehog (DHH). In the absence of Hh ligands, PTCH1 suppresses the activity of another membrane protein called Smoothened (SMO), thereby inhibiting downstream signaling and cell proliferation. When an Hh ligand binds to PTCH1, this suppression is relieved; SMO becomes active, leading to activation of GLI transcription factors and gene expression that promotes cell growth and differentiation. Mutations or loss-of-function variants in PTCH1 are linked to several disorders, including Gorlin Syndrome and certain cancers.
Relieves inhibition of Smoothened (SMO) upon binding to Hedgehog ligands, activating the Hedgehog signaling pathway.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Patched homolog 1 (PTCH1).